<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="HE93A94BE409047D393DA505470C37E37" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>119 HR 5316 IH: Drug Shortage Compounding Patient Access Act of 2025</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2025-09-11</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">119th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 5316</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20250911">September 11, 2025</action-date><action-desc><sponsor name-id="H001086">Mrs. Harshbarger</sponsor> (for herself and <cosponsor name-id="C001103">Mr. Carter of Georgia</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To amend the Federal Food, Drug, and Cosmetic Act to ensure patients have access to certain shortage and urgent-use compounded medications, and for other purposes.</official-title></form><legis-body id="HC8A2971A741B40E68E782CE2F027E88E" style="OLC"> 
<section id="H942647CE271445FD8F62E0B400A862AD" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Drug Shortage Compounding Patient Access Act of 2025</short-title></quote>.</text></section> <section id="H38C7DDF8FE0C45659051A74361E274C1"><enum>2.</enum><header>Pharmacy compounding</header> <subsection id="H5A201174D074424B8293C809B87975A8"><enum>(a)</enum><header>Compounding for urgent administration to patients</header><text display-inline="yes-display-inline">Section 503A(a) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/353a">21 U.S.C. 353a(a)</external-xref>) is amended—</text> 
<paragraph id="H69FBD6EC5C2343D09943FB269419FC76"><enum>(1)</enum><text display-inline="yes-display-inline">in paragraph (1), by striking <quote>or</quote> at the end;</text></paragraph> <paragraph id="H068EB32609D7461B879C1E2E4F006F19"><enum>(2)</enum><text>in paragraph (2)(B)(ii)(II), by striking the period at the end and inserting <quote>; or</quote>; and</text></paragraph> 
<paragraph id="H3038B4A760864CC19AB95E65395C8323"><enum>(3)</enum><text>by adding at the end the following:</text> <quoted-block style="OLC" id="H4F4A5874488B4DD8A43E3F8EAE4CB157" display-inline="no-display-inline"> <paragraph id="H47910F60F3024C309E6A0FCBB2A8784E"><enum>(3)</enum><text display-inline="yes-display-inline">notwithstanding the requirement in the matter preceding paragraph (1) that the drug product is compounded for an identified individual patient based on a valid prescription order or notation described in such matter, is by a licensed pharmacist or licensed physician and the compounded drug product is compounded for distribution in limited quantities to a licensed prescriber for urgent administration to a patient in a hospital or other clinical setting, provided that all of the following are met:</text> 
<subparagraph id="HD55703F2CEF14723816AF1311C4076CC"><enum>(A)</enum><text>The drug product appeared on the drug shortage list in effect under section 506E at any time during the 60-day period ending on the date of the compounding, distribution, or dispensing of the drug product.</text></subparagraph> <subparagraph id="H1C7F347CDD9744E7B7FE4212A5B099C3"><enum>(B)</enum><text>The licensed prescriber certifies by notation on the order to the compounding pharmacist or physician that the licensed prescriber has made reasonable attempts to obtain, and has not been able to obtain, to address the urgent medical need a drug product that is compounded by an outsourcing facility in accordance with section 503B with the same active ingredient and the same route of administration.</text></subparagraph> 
<subparagraph id="H8461447AFB9348209B94F88C28070D51"><enum>(C)</enum><text>The compounded drug product is labeled with a beyond-use-date in accordance with applicable United States Pharmacopeia standards.</text></subparagraph> <subparagraph id="HC2D9574243D743D69177A15E188055A9"><enum>(D)</enum><text>The licensed pharmacist or licensed physician marks the packaging of the compounded drug product with text—</text> 
<clause id="H1CDCEED913704107BA67DEA5178EF305"><enum>(i)</enum><text>indicating that the drug product is provided to the hospital or other clinical setting only for urgent administration to a patient; and</text></clause> <clause id="H2C91435B85C849949E7F8AC164C34E0E"><enum>(ii)</enum><text>requesting that the hospital or other clinical setting provide to the compounding pharmacist or physician the records that identify the patient or patients to whom the drug products were administered within—</text> 
<subclause id="H3478FB0AF6584B17A77C6157B6B3E55F"><enum>(I)</enum><text>7 days of each such patient receiving such medication; or</text></subclause> <subclause id="H8B8F1E29D4194EAABF348EADB372E831"><enum>(II)</enum><text>7 days of each such patient being discharged.</text></subclause></clause></subparagraph> 
<subparagraph id="HD46897B34E804F0D8B807BF92378731E"><enum>(E)</enum><text>Upon receipt of records requested pursuant to subparagraph (D)(ii), the licensed pharmacist or licensed physician ensures that the patient information in such records is linked with the respective order.</text></subparagraph> <subparagraph id="H4D35ADCBA5674D998674EB62E3123D41"><enum>(F)</enum><text>The licensed pharmacist or licensed physician reports adverse events associated with the compounded drug product as soon as possible but not later than 15 days after becoming aware of such events to the MedWatch Adverse Event Reporting program of the Food and Drug Administration (or any successor program).</text></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection> 
<subsection id="HD9BDA944C9924094ADF3D7F0AB6009ED"><enum>(b)</enum><header>Definition</header><text display-inline="yes-display-inline">Paragraph (2) of section 503A(b) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/353a">21 U.S.C. 353a(b)(2)</external-xref>) is amended to read as follows:</text> <quoted-block style="OLC" id="HCC17027AC3744E9CB0B3EEFB0283D1B7" display-inline="no-display-inline"> <paragraph id="HD144B2442AC24F7D98E2647C27A4A9AD"><enum>(2)</enum><header>Definition</header><text display-inline="yes-display-inline">For purposes of paragraph (1)(D), the term <quote>essentially a copy of a commercially available drug product</quote> does not include—</text> 
<subparagraph id="H149F92438B8A4FE1BB31DB641ED19F3F"><enum>(A)</enum><text>a drug product in which there is a change, made for an identified individual patient, which produces for that patient a significant difference, as determined by the prescribing practitioner, between the compounded drug and the comparable commercially available drug product; or</text></subparagraph> <subparagraph id="H0FD95C0FEB0A4FA1BCD806B62C02A2C1"><enum>(B)</enum><text display-inline="yes-display-inline">a drug product that meets each of the following conditions:</text> 
<clause id="HE4A39AD9A8EB42A2BD600AE0CB43E071"><enum>(i)</enum><text display-inline="yes-display-inline">At any time during the 60-day period ending on the date of the compounding, distribution, or dispensing, the drug product appeared on the drug shortage list in effect under section 506E.</text></clause> <clause id="H79F61148E0DB4B1DB223B8B63DAF468C"><enum>(ii)</enum><text>If the drug product is not compounded for an identified individual patient based on a valid prescription order or notation, notwithstanding such requirement in the matter preceding paragraph (1) of subsection (a), the drug product—</text> 
<subclause id="HBEFBC6F78659467E8B18ED593463178D"><enum>(I)</enum><text>is labeled in accordance subparagraphs (C) and (D) of subsection (a)(3); and</text></subclause> <subclause id="H0C7B1D8CC3474F2EB4A8DCA0CD9B5857"><enum>(II)</enum><text>is documented by the compounding pharmacist or physician in accordance with subparagraphs (E) and (F) of subsection (a)(3).</text></subclause></clause></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></subsection></section> 
<section id="HF1A0998D14C34227AE164282B3866281"><enum>3.</enum><header>Mitigating drug shortages through improved reporting</header><text display-inline="no-display-inline">Section 506C of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/356c">21 U.S.C. 356c</external-xref>) is amended—</text> <paragraph id="H17A041F09D2A471D8771727ED8DA1449"><enum>(1)</enum><text>in the section heading, by inserting <header-in-text level="section" style="OLC"><quote>OR SURGE IN DEMAND FOR</quote></header-in-text> after <header-in-text level="section" style="OLC"><quote>PRODUCTION OF</quote></header-in-text>;</text></paragraph> 
<paragraph id="HBF5AEB481D3D4768A25A424E9AFF0C56"><enum>(2)</enum><text>in subsection (a), in the matter following paragraph (2)—</text> <subparagraph id="H1F158F8398DA4F928134211ACF1DD187"><enum>(A)</enum><text>by striking <quote>or an interruption of the manufacture of the drug</quote> and inserting <quote>, an interruption of the manufacture of the drug, or a surge in demand for the drug</quote>;</text></subparagraph> 
<subparagraph id="H9D080684421E4F19A7D6FEF8CA8F7F33"><enum>(B)</enum><text>by striking <quote>such discontinuance or interruption</quote> and inserting <quote>such discontinuance, interruption, or surge in demand</quote>;</text></subparagraph> <subparagraph id="HFF38E919143E4689944271E9E22CECEC"><enum>(C)</enum><text>by striking <quote>the discontinuation or interruption</quote> and inserting <quote>the discontinuation, interruption, or surge in demand</quote>;</text></subparagraph> 
<subparagraph id="H6E9779973D674E0FBECC612C6C20F34B"><enum>(D)</enum><text display-inline="yes-display-inline">by striking <quote>such discontinuation or interruption, the source</quote> and inserting <quote>such discontinuation, interruption, or surge in demand, the source</quote>; and</text></subparagraph> <subparagraph id="HAEF2AE0B873A42F497C452E960AEA341"><enum>(E)</enum><text>by striking <quote>such discontinuation or interruption; the expected duration of the interruption;</quote> and inserting <quote>such discontinuation, interruption, or surge in demand; the expected duration of the interruption or surge in demand</quote>;</text></subparagraph></paragraph> 
<paragraph id="H8C2CB9E985BD4F7CBBA27947210E2D4D"><enum>(3)</enum><text>in subsection (b), by striking paragraphs (1) and (2) and inserting the following:</text> <quoted-block style="OLC" id="HE6A00F5B48F34170B45FD2AD1E307FD2" display-inline="no-display-inline"> <paragraph id="H75339A413BBC418391A9819E20E708EA"><enum>(1)</enum><text display-inline="yes-display-inline">in the case of a notice of a discontinuance or interruption in the manufacture of a drug—</text> 
<subparagraph id="H2AF45CAA1410442C8913A0952CDE2650"><enum>(A)</enum><text>at least 6 months prior to the date of the discontinuance or interruption; or</text></subparagraph> <subparagraph id="H2727FED5F9E440DE91AD3873A8871083"><enum>(B)</enum><text>if compliance with subparagraph (A) is not possible, as soon as practicable; or</text></subparagraph></paragraph> 
<paragraph id="H9E2ABC1A04D44180B59D70926ED82474"><enum>(2)</enum><text>in the case of a notice of a surge in demand for a drug, as soon as practicable.</text></paragraph><after-quoted-block>;</after-quoted-block></quoted-block></paragraph> <paragraph id="H74C2CBFC582B48339E1FF354ADDCACF6"><enum>(4)</enum><text>in subsection (c)—</text> 
<subparagraph id="H1D4DCC658518441FBB69073DD3976736"><enum>(A)</enum><text>by striking <quote>discontinuance or interruption</quote> and inserting <quote>discontinuance, interruption, or surge in demand</quote>; and</text></subparagraph> <subparagraph id="H1D02296BE3354EF7907F16A351A50AB0"><enum>(B)</enum><text>by inserting <quote>and outsourcing facilities (as defined in section 503B(d))</quote> after <quote>patient organizations</quote>; and</text></subparagraph></paragraph> 
<paragraph id="H2DD849251E174A298B90DE392C193A7C"><enum>(5)</enum><text>in subsection (h)—</text> <subparagraph id="H110000CDD4484BE28D176A0A0880C4BD"><enum>(A)</enum><text>in paragraph (1), by striking <quote>and that is subject to section 503(b)(1)</quote> and inserting <quote>or the active pharmaceutical ingredient of such a drug</quote>;</text></subparagraph> 
<subparagraph id="H29330E08524A4614996F9A8AA19490A6"><enum>(B)</enum><text>by amending paragraph (2) to read as follows:</text> <quoted-block style="OLC" id="H5834853A457D4D559763E46935BD9FA7" display-inline="no-display-inline"> <paragraph id="HB12FC586EA954C7C8B572175E8ED9B03"><enum>(2)</enum><text display-inline="yes-display-inline">the term <quote>drug shortage</quote> or <quote>shortage</quote>, with respect to a drug, means a period of time with the demand or projected demand for the drug within the United States exceeds the supply of the drug, taking into consideration—</text> 
<subparagraph id="HF6634406C7A748F982EB64A7675D7642"><enum>(A)</enum><text>how the drug is prepared or dispensed, including the route of administration and dosage form; and</text></subparagraph> <subparagraph id="H810B2815AFD245A3869E7B0C25C9B919"><enum>(B)</enum><text>information reported by manufacturers, health care professionals, and patients;</text></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></subparagraph> 
<subparagraph id="H4DA0BB8A83B94862940BDD8AF26FA3EB"><enum>(C)</enum><text>in paragraph (3)(B), by striking the period at the end and inserting <quote>; and</quote>; and</text></subparagraph> <subparagraph id="H53957EF4BDF94D558E2C3AB26C33C70F"><enum>(D)</enum><text>by adding at the end the following:</text> 
<quoted-block style="OLC" id="HE7FF5C0F5CFA4250A726F5728244DEBF" display-inline="no-display-inline"> 
<paragraph id="HB78AE2AB0D394862A040BE1202502FEB"><enum>(4)</enum><text display-inline="yes-display-inline">the term <quote>surge</quote> means an increase in demand or projected demand for a drug that the manufacturer likely will be unable to meet without meaningful shortfall or delay.</text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></subparagraph></paragraph></section> <section id="H431A44CD8B024DCD9B6E5FD6CCCE32D5"><enum>4.</enum><header>Outsourcing facility compounding</header><text display-inline="no-display-inline">Section 503B of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/353b">21 U.S.C. 353b</external-xref>) is amended—</text> 
<paragraph id="H95F57A48E99546E9A2528B60C69F799D"><enum>(1)</enum><text display-inline="yes-display-inline">in subsection (a)(2)(A)(ii)—</text> <subparagraph id="H10752114999F4C52A80528FB33597F21"><enum>(A)</enum><text>by striking <quote>appears</quote> and inserting <quote>appeared</quote>; and</text></subparagraph> 
<subparagraph id="H8FE57FE439F1400A8EA5B4F2D3C648BC"><enum>(B)</enum><text>by striking <quote>at the time of</quote> and inserting <quote>at any time during the 180-day period ending on the date of </quote>;</text></subparagraph></paragraph> <paragraph id="H2C41C527A6E54D41A9125404CB52F519"><enum>(2)</enum><text>in subsection (a)(10)(A)(iii)—</text> 
<subparagraph id="HA82F2437F90E4BFDA478F946EA693A05"><enum>(A)</enum><text>in subclause (VIII), by striking the semicolon at the end and inserting <quote>; and</quote>;</text></subparagraph> <subparagraph id="H5BFF53E4EC7B4577A74D9EAB123D90BA"><enum>(B)</enum><text>by striking subclause (IX); and</text></subparagraph> 
<subparagraph id="H4855DDBADA1648A5B9CF02DADEB4BDB8"><enum>(C)</enum><text>by redesignating subclause (X) as subclause (IX);</text></subparagraph></paragraph> <paragraph id="H6D7F3863DDD342A19F9C82DDB8D1281A"><enum>(3)</enum><text>by redesignating the 2 subsections (d) (relating to definitions and relating to obligation to pay fees) as subsections (e) and (f), respectively; and</text></paragraph> 
<paragraph id="HFB039C9FF3E246858A5D26E83AB3F016"><enum>(4)</enum><text>by inserting after subsection (c) the following:</text> <quoted-block style="OLC" id="HF6027ABB2EE2433F883902137F05DB65" display-inline="no-display-inline"> <subsection id="H9E13A1EF3FF543C6875BFC6A80DE5C50"><enum>(d)</enum><header>List of identified bulk drug substances</header><text display-inline="yes-display-inline">The Secretary shall make publicly available annual updates on the evaluation of bulk drug substances for purposes of the list maintained under subsection (a)(2)(A)(i).</text></subsection><after-quoted-block>;</after-quoted-block></quoted-block></paragraph></section> 
<section id="H1CAF89E16AB547F88B0AC3E4C03336B6"><enum>5.</enum><header>Clarifying provisions; labeling requirement</header><text display-inline="no-display-inline">Section 503A of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/353a">21 U.S.C. 353a</external-xref>) is amended—</text> <paragraph id="H4F93620F88A34558B77BBE323FF93C54"><enum>(1)</enum><text display-inline="yes-display-inline">by striking subsection (b)(3)(B) and the matter following such subsection and inserting the following:</text> 
<quoted-block style="OLC" id="HD376F296400D42C1A13DE976DC2D813C" display-inline="no-display-inline"> 
<subparagraph id="H7522BD18661F483FA2ED40958009FC27"><enum>(B)</enum><text display-inline="yes-display-inline">such drug product is labeled as follows: <quote>This medication has been compounded for dispensing to an individual patient and has not been approved by the Food and Drug Administration</quote>.</text></subparagraph><after-quoted-block>; and</after-quoted-block></quoted-block></paragraph> <paragraph id="H4EA73A394BCD48CA869F220E92D36051"><enum>(2)</enum><text display-inline="yes-display-inline">in subsection (b)(1)(A)(i)(I) by striking <quote>National Formulary monograph</quote> and inserting <quote>National Formulary drug or dietary supplement monograph</quote>.</text></paragraph></section> 
</legis-body></bill>

